Nexus Pharmaceuticals, a United States-based healthcare company, announced yesterday that it has launched its Procainamide HCL Injection, USP following US Food and Drug Administration approval.

The product is offered as a multi dose vial containing 1,000 mg per 2 mL (500 mg/mL) or as a multi dose vial containing 1,000 mg per 10 mL (100 mg/mL) and is an AP Rated generic equivalent. It is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening.

Mariam Darsot, president of Nexus Pharmaceuticals Inc, said, 'The introduction of Procainamide HCL Injection, USP further illustrates Nexus Pharmaceuticals' commitment to meeting market needs and shortages in the short term, while broadening the availability of effective generic products for the long term.'